GSA Capital Partners’s ALX Oncology ALXO Stock Holding History

GSA Capital Partners’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$138K	Sell	68,987 -23,667	-26%	-$45.1K	0.01%	1524
2025 Q4	$105K	Buy	92,654 +4,489	+5%	+$6.8K	0.01%	1524
2025 Q3	$161K	Buy	88,165 +6,839	+8%	+$5.92K	0.01%	1470
2025 Q2	$34K	Buy	+81,326	New	+$41K	﹤0.01%	1677
2024 Q4	–	Sell	-48,204	Closed	-$88K	–	1576
2024 Q3	$88K	Buy	+48,204	New	+$179K	0.01%	1501
2024 Q2	–	Sell	-10,289	Closed	-$115K	–	1595
2024 Q1	$115K	Buy	+10,289	New	+$145K	0.01%	1476
2023 Q3	–	Sell	-12,730	Closed	-$96K	–	1465
2023 Q2	$96K	Buy	+12,730	New	+$83.3K	0.01%	1380
2022 Q4	–	Sell	-16,114	Closed	-$154K	–	1431
2022 Q3	$154K	Buy	+16,114	New	+$188K	0.02%	1289
2022 Q1	–	Sell	-24,203	Closed	-$520K	–	1377
2021 Q4	$520K	Buy	+24,203	New	+$1.04M	0.07%	574

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

GSA Capital Partners's ALXO Position: Q1 2026 in Review

GSA Capital Partners reduced its ALX Oncology (ALXO) stake by 26% in Q1 2026, selling an estimated $45.1K and leaving 68,987 shares worth $138K. The position accounts for 0.01% of the portfolio, ranked #1524.

GSA Capital Partners first reported a position in ALXO in Q4 2021 and has held it in 9 quarters since. The position peaked at $520K in Q4 2021. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

GSA Capital Partners held 68,987 shares of ALX Oncology worth $138K as of Q1 2026.
GSA Capital Partners sold 23,667 ALX Oncology shares in Q1 2026, an estimated $45.1K.
ALX Oncology made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1524 holding.
GSA Capital Partners first reported a position in ALX Oncology in Q4 2021 and has held it in 9 quarters since.
GSA Capital Partners's ALX Oncology position peaked at $520K in Q4 2021.
69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.